NM
OKUR

Newtyn Management’s OnKure Therapeutics OKUR Stock Holding History

Newtyn Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,098
Closed -$56K – 88
2022
Q2 		$56K Buy
+2,098
New +$48.8K 0.01% 80

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Newtyn Management's OKUR Position: Q3 2022 in Review

Newtyn Management sold out of OnKure Therapeutics (OKUR) in Q3 2022, closing a stake of 2,098 shares — an estimated $56K sold.

Newtyn Management first reported a position in OKUR in Q2 2022 and held it in 1 quarter. The position peaked at $56K in Q2 2022. 33 funds tracked by Wall St. Rank hold OKUR as of Q3 2022.

  • Newtyn Management reported no remaining OnKure Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Newtyn Management sold 2,098 OnKure Therapeutics shares in Q3 2022, an estimated $56K.
  • Newtyn Management first reported a position in OnKure Therapeutics in Q2 2022 and held it in 1 quarter.
  • Newtyn Management's OnKure Therapeutics position peaked at $56K in Q2 2022.
  • 33 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2022.

Based on Newtyn Management's 13F filing for Q3 2022, filed 14 Nov 2022.